eFFECTOR Therapeutics (EFTR) Competitors $0.0002 0.00 (-50.00%) As of 09:32 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock EFTR vs. HSTO, ONCSQ, PXMD, ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, and BFRIWShould you be buying eFFECTOR Therapeutics stock or one of its competitors? The main competitors of eFFECTOR Therapeutics include Histogen (HSTO), OncoSec Medical (ONCSQ), PaxMedica (PXMD), 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry. eFFECTOR Therapeutics vs. Its Competitors Histogen OncoSec Medical PaxMedica 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera Histogen (NASDAQ:HSTO) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends. Is HSTO or EFTR more profitable? Company Net Margins Return on Equity Return on Assets HistogenN/A N/A N/A eFFECTOR Therapeutics N/A N/A N/A Which has better valuation and earnings, HSTO or EFTR? Histogen has higher revenue and earnings than eFFECTOR Therapeutics. Histogen is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHistogen$19K7.12-$10.62M-$2.81-0.01eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.080.00 Which has more volatility & risk, HSTO or EFTR? Histogen has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, eFFECTOR Therapeutics has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500. Does the media refer more to HSTO or EFTR? In the previous week, Histogen's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score. Company Overall Sentiment Histogen Neutral eFFECTOR Therapeutics Neutral Do institutionals & insiders believe in HSTO or EFTR? 57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 3.3% of Histogen shares are held by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryHistogen beats eFFECTOR Therapeutics on 4 of the 7 factors compared between the two stocks. Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EFTR vs. The Competition Export to ExcelMetriceFFECTOR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1K$761.07M$5.57B$9.35BDividend YieldN/A4.84%3.80%4.06%P/E Ratio0.001.3928.0719.85Price / SalesN/A25.51441.7699.96Price / CashN/A19.5635.8457.94Price / Book0.006.728.265.67Net Income-$35.81M-$4.32M$3.24B$257.80M7 Day PerformanceN/A0.00%0.51%1.07%1 Month PerformanceN/A1.41%7.99%11.31%1 Year PerformanceN/A-1.96%28.68%17.01% eFFECTOR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EFTReFFECTOR Therapeutics0.0734 of 5 stars$0.00-50.0%N/AN/A$1KN/A0.0010HSTOHistogenN/A$0.00flatN/A-83.3%$1K$19K0.0020ONCSQOncoSec MedicalN/AN/AN/AN/A$1KN/A0.0040PXMDPaxMedica0.1265 of 5 stars$0.00flatN/A-100.0%$1KN/A0.002ATNFW180 Life SciencesN/A$0.01-4.8%N/A-25.0%$0.00N/A0.007Gap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01flatN/AN/A$0.00N/A0.002Gap DownAIMDWAinosN/A$0.12+0.2%N/A+121.1%$0.00$106.21K0.0040Gap DownALVOWAlvotechN/A$1.93+1.6%N/A-28.0%$0.00$585.60M0.004Gap UpACABWAtlantic Coastal Acquisition Corp. IIN/A$0.02flatN/A-56.1%$0.00N/A0.0015BFRIWBiofronteraN/A$0.09-14.2%N/AN/A$0.00$38.00M0.0070Gap Down Related Companies and Tools Related Companies Histogen Alternatives OncoSec Medical Alternatives PaxMedica Alternatives 180 Life Sciences Alternatives 4D pharma Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Alvotech Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Biofrontera Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EFTR) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
